Modification of conventional risk factors in coronary artery disease;Risikofaktorenmodifizierung koronarkranker

Wiener Medizinische Wochenschrift

Volumn 154, Issue 11-12, 2004, Pages 282-288

  Völler, Heinz ^a  

^a Klinik am See   (Germany)

Author keywords

Coronary artery disease; Patient education; Rehabilitation; Risk adjusted secondary prevention

Indexed keywords

INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ALCOHOL CONSUMPTION; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FOLLOW UP; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEART INFARCTION; HUMAN; HYPERLIPOPROTEINEMIA; HYPERTENSION; LIFESTYLE; LOW CALORY DIET; NUTRITION; OBESITY; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; PROGNOSIS; RISK FACTOR; STROKE; WEIGHT REDUCTION;

CHOLESTEROL, LDL; CORONARY DISEASE; GERMANY; HEALTH EDUCATION; HUMANS; LIFE STYLE; MYOCARDIAL INFARCTION; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE;

EID: 3142668587     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-004-0074-z     Document Type: Article

References (60)

1. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E (1999) Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 106: 179-184
2. Ballor DL, Keesey RE (1991) A meta-analysis of the factors affecting exercise-induced changes in body mass, fat mass and fat free mass. Int J Obes 15: 717-726
3. Bonetti PO, Lerman LO, Napoli C, Lerman A (2003) Stalin effects beyond lipid lowering - are they clinically relevant? European Heart Journal 24: 225-248
4. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwanz SL, Scheinbaum ML, Seaton TB (1999) Sibutramine produces dose-related weight loss. Obes Res 7: 189-198
5. Bruckert E, Giral P, Tellier P (2003) Perspectives in cholesterol-lowering therapy. Circulation 107: 3124-3128
6. Bucher HC, Hengstler P, Schindler C, Meier G (2002) N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 112: 298-304
7. Bundeszentrale für gesundheitliche Aufklärung, Jugendliche Raucher Veränderungen des Rauchverhaltens und Ansätze für die Prävention, Ergebnisse der Wiederholungsbefragung: Drogenaffinität Jugendlicher in der Bundesrepublik Deutschland 2001. http://www.bzga.de/ bzga_stat/studien/material/jug_rauch.pdf (03.03.2004)
8. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM (1989) Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 2: 757-761
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ (2003) The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 Report. JAMA 289: 2560-2571
10. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24: 987-1003
11. Davidson MH, Hauptmann J, DiGirolamo M (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. A randomized controlled trail. J Am Med Assoc 281: 235-242
12. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of the European and other societies (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prevent Rehab 10 [Suppl 1]: S 1-78
13. De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N (1999) Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 99: 779-785
14. Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403
15. Dietz R, Rauch B (2003) Leitlinie zur Diagnose und Behandlung der chronischen koronaren Herzerkrankung der Deutschen Gesellschaft für Kardiologie - Herz- und Kreislaufforschung (DGK). Z Kardiol 92: 501-521
16. Dovifat C, Hartung R, Linke S, Breitkreuz B, Kamke W, Wegscheider K, Völler H (1999) Wahrnehmung und Akzeptanz des persönlichen Risikoprofils im Rahmen einer stationären Rehabilitation. DRV Schriften 12: 225-226
17. EUROASPIRE II Study group (2001) Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart survey Programme. Eur Heart J 22: 554-572
18. Executive summary of the clinical guidelines on the identification, evaluation, and measurement of overweight and obesity in adults. Arch Intern Med 1998; 158: 1855-1867
19. Executive summary of the third report of the National Cholesterol Education Program (NCEP) (2001) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 285: 2486-2497
20. Fagard RH (1999) Physical activity in the prevention and treatment of hypertension in the obese. Med Sci Sports Exerc 31[Suppl 11]: 624-630
21. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383-393
22. Guercolini R (1997) Mode of action of orlistat. Int J Obes Relat Metab Disord 21: 512-523
23. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234
24. Hauner H, Köster I, von Ferber L (2003) Prävalenz des Diabetes mellitus in Deutschland 1998-2001 Dtsch Med Wochenschr 128: 2632-2637
25. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22
26. Heidrich J, Wellmann J, Hense H-W, Siebert E, Liese AD, Löwel H, Keil U (2003) Klassische Risikofaktoren für Herzinfarkt und Gesamtsterblichkeit in der Bevölkerung. Z Kardiol 92: 445-454
27. Hense HW, Schulte H, Löwel H, Assmann G, Keil U (2003) Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - results from the MONICA Augsburg and the PROCAM cohorts Eur Heart J 24: 937-945
28. Hersey III WC, Graves JE, Pollock ML, Gingerich R, Shireman RB, Heath GW, Spierto F, McCole SD, Hagberg JM (1994) Endurance exercise training improves body composition and plasma insulin responses in 70-79-year-old men and women. Metabolism 43: 847-854
29. Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, Zavoral JH, Aronne LJ (1999) University of Colorado Health Sciences Center, Denver, USA. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting - A 1 year study. Am J Clin Nutr 69 (6): 1108-1116
30. Hoberg E, Stockinger J, Bestehorn K, Wegscheider K. für die HANSA-Studiengruppe (2002) Verbesserung des Risikofaktorenprofils durch drei halbtägige Auffrischungskurse innerhalb des ersten Jahres nach kardio-logischer Rehabilitation - Ergebnisse der HANSA-Studie. Z Kardiol 91[Suppl 5]: P 141
31. Jakicic JM, Winters C, Lang W, Wing RR (1999) Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women. JAMA 282: 1554-1560
32. Kelley DE, Goodpaster BH (1999) Effects of physical activity on insulin and glucose tolerance in obesity. Med Sci Sports Exerc 31[Suppl 11]: 619-623
33. Khot UM, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ (2003) Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290: 898-904
34. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J (1990) Blood pressure, stroke, and coronary heart disease - Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335: 765-774
35. Malmberg K, Norhammar A, Wedel H, Rydén L (1999) Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Circulation 99: 2626-2632
36. Miller WC, Koceja DM, Hamilton EJ (1997) A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet with exercise intervention. Int J Obes 21: 941-947
37. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289: 76-79
38. National Institutes of Health (NIH) and National Heart, Lung and Blood Institute (NHLBI) (1998) Clinical Guidelines on the indentification, evaluation and treatment of overweight an obesity in adults. Evidence based report, Bethesda, MD:NIH NHLBI www.nhlbi.nih.gov
39. Nationales Programm für Versorgungs-Leitlinien bei der Bundesärztekammer, Nationale Versorgungs-Leitlinie, Diabetes mellitus Typ 2: 1. Auflage - Mai 2002, Korrigierte Version vom 01.07.2002
40. Nawaz H, Katz DL (2001) American College of Preventive Medicine Practice policy statement. Weight management counseling of overweight adults. Am J Prev Med 21: 73-78
41. NIH Consensus Development Conference Statement (1992) Gastrointestinal surgery for severe obesity. Am J Clin Nutr 55[Suppl]: S 615-619
42. Norhammer A, Malmberg K, Rydén L, Tornvall P, Stenestrand U, Wallentin L (2003) For the register of information and knowledge about Swedish heart intensive care admissions (RIKS-HIA). Eur Heart J 24: 838-844
43. Norhammer A, Tenerz Ä, Nilsson G, Hamsten A, Efendic S, Rydén L, Malmberg K (2002) Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359: 2140-2144
44. Romijn JA, Cycle EF, Sidossis LS, Gastaldelli A, Horowitz JF, Endert E, Wolfe RR (1993) Regulation of endogenous fat and carbohydrate matabolism in relation to exercise intensity and duration. Am J Physiol 265: 380-391
45. Ross R, Rissanen J (1994) Mobilization of visceral and subcutaneous adipose tissue in response to energy restriction and exercise. Am J Clin Nutr 60: 695-703
46. Ryan D, Kaiser HP, Bray GA (1995) Sibutramine: A novel new agent for obesity treatment. Obesity Res 3: 553s-559s.
47. Sacks F, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica W, Arnold JMO, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (CARE). N Engl J Med 335: 1001-1009
48. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
49. Shepherd J (2003) Combined lipid lowering drug therapy for the effective treatment of hypercholesterolaemia. Eur Heart J 24: 685-689
50. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M (1998) Randomized placebo-controlled trail of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 352: 167-172
51. Stefanick ML (1999) Physical activity for preventing and treating obesity-related dyslipoproteinemias. Med Sci Sports Exerc 31[Suppl 11]: 609-618
52. Thompsen D, Edelsberg J, Colditz GA, Bird AP, Oster G (1999) Lifetime Health and Economic Consequences of Obesity Ach Intern Med 159: 2177-2183
53. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M (2001) Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1350
54. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D (2002) Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 287: 1003-1010
55. Völler H, Bestehorn K, Wegscheider K (2003) ROG-study: control of blood pressure and lipid profil in routine cardiovascular rehabilitation Eur Heart J 24[Suppl]: P3311
56. Völler H, Klein G, Gohlke H, Dovifat C, Binting S, Müller-Nordhorn J, Willich SN (2000) Für die PIN-Studiengruppe. Sekundärprävention Koronarkranker nach stationärer Rehabilitation. Dtsch Med Wochenschr 125: 1457-1461
57. Völler H, Schmailzl KJG, Bjarnason-Wehrens B. Adipositas und Herz- und Kreislauferkrankungen - Grundlagen und therapeutische Konsequenzen. Z Kardiol (in Druck)
58. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense H-W, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodríguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescioet F (2003) Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289: 2363-2369
59. Wood PD, Stefanick ML, Williams PT, Haskell WL (1991) The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in over-weight. N Engl J Med 325: 461-466
60. Zidek W, Düsing R, Haller H, Middeke M, Paul M, Schmieder R, Schrader J (2003) Neue Empfehlungen der Deutschen Hochdruckliga zur medikamentösen Therapie der Hypertonie. Dtsch Med Wochenschr 128: 2468-2469